BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6977170)

  • 1. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Macdonald JS; Marsoni S; Bruno S; Poster D
    Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 3. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
    Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
    Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
    Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
    Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.
    Dillman RO; Mick R; McIntyre OR
    J Clin Oncol; 1989 Apr; 7(4):433-8. PubMed ID: 2784491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
    Spiers AS
    Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
    Webster HK; Wiesmann WP; Pavia CS
    Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
    [No Abstract]   [Full Text] [Related]  

  • 14. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
    O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
    Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 16. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
    Spiers AS; Parekh SJ
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose deoxycoformycin in lymphoid malignancy.
    Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
    J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
    Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
    Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
    [No Abstract]   [Full Text] [Related]  

  • 19. Deoxycoformycin in the treatment of leukemias and lymphomas.
    Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
    Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.